Source-grounded facts extracted from ABVC BIOPHARMA, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ABVC BIOPHARMA, INC. reported that prior financial statements should not be relied upon.
“atters disclosed in this Item 4.02 with its independent registered public accounting firm, Simon & Edward, LLP. Due to the above, the Company determined that it has a material weakness in its internal controls over financial reporting and shall include such determination in its Annual Report on Form”
ABVC BIOPHARMA, INC. issued an aggregate of 1,500,250 shares of the Company’s common stock of common stock to accredited investors and Non-U.S. Persons for aggregate amount of $2,275,468.
“the Company’s chairman for the maximum time permitted by law. Between May 26, 2025, and January 6, 2026, the Company accepted additional subscriptions in the aggregate amount of $2,275,468 on the same terms and conditions as the Reg S Offering (the “ Additional Subscriptions ”); the Company’s Board of Directors approved the Additional Subscriptions on January 12,”
ABVC BIOPHARMA, INC. issued an aggregate of 1,987,557 shares of common stock to 43 Non-U.S. Persons for aggregate gross proceeds of approximately $1,289,750.
“the Company sold an aggregate of 1,987,557 shares (the “ Shares ”) of its Common Stock to 43 Non-U.S. Persons (as defined in Regulation S under the Securities Act). The offer and sale of the Shares was exempt from the registration provisions of the Securities Act, pursuant to Regulation S thereunder (“ Regulation S ”); the Company received aggregate gross proceeds of approximately $1,289,750 for the Shares”
ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“May 13, 2025, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that the Company has met the Bid Requirement and therefore the matter is closed. Accordingly, no reverse stock split is necessary at this time.”
ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5550(b)(1)).
“December 31, 2024, because its stockholders’ equity was $723,959, as of April 23, 2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it no longer comply with Listing Rule 5550(b)(1) (the “ Listing Rule ”). On May 5, 2025, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders’ equity of $7,956,295, the Company c”
ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 24, 2025, we received a letter from the listing qualifications staff (the “ Staff ”) of Nasdaq informing us that, as reported in our Annual Report on Form 10-K for the year ended December 31, 2024, because our stockholders’ equity was $723,959, as of April 23, 2025, we did not meet the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with the Listing Rule. We have 45 calendar days to submit a plan to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar days from the”
ABVC BIOPHARMA, INC. reported that prior financial statements should not be relied upon.
“he matters disclosed in this Item 4.02 with its independent registered public accounting firm, Simon & Edward, LLP. Due to the above, the Company determined that it has a material weakness in its internal controls over financial reporting and included such determination in its Annual Report on Form”
Uttam Patil changed role as interim Chief Financial Officer at ABVC BIOPHARMA, INC..
“While the Company is looking for a full-time Chief Financial Officer to fill the vacancy created by Leeds Chow’s resignation, the Company’s CEO, Uttam Patil will serve as the interim Chief Financial Officer of the Company.”
Leeds Chow resigned as Chief Financial Officer at ABVC BIOPHARMA, INC..
“On March 5, 2025, Mr. Leeds Chow, the Chief Financial Officer (“CFO”) of ABVC BioPharma, Inc. (the “Company”) notified the Company of his resignation as CFO.”
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). On July 12, 2024, the Company disclosed that Nasdaq had informed it that its stock had failed to maintain the minimum bid price over the preceding 30 business days. At that time, the Company was given until January 6, 2025, to regain compliance. The current extension was granted based on the Company’s adherence to other l”
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as”
Uttam Patil was appointed as interim Chief Financial Officer at ABVC BIOPHARMA, INC..
“The Company’s CEO, Uttam Patil, will assume the duties of interim Chief Financial Officer until the parties settle the disagreement and Leeds resumes his position as CFO.”
Leeds Chow departed as Chief Financial Officer at ABVC BIOPHARMA, INC..
“due to disagreements regarding salaries due and payable, Mr. Chow has informed the Company that he is suspending his work as CFO.”
ABVC BIOPHARMA, INC. terminated Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-05-16).
“On May 16, 2024, the Company’s board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not proceed with the transfer of land ownership at this time”
ABVC BIOPHARMA, INC. entered into Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-02-08).
“On February 8, 2024, ABVC BioPharma, Inc. (the “ Company ”) filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang was going to transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p (effective 2024-05-14).
“On May 14, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC’s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the “ Licensed Products ”), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the “ Oncox Agreement ”).”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (effective 2024-05-08).
“ompany entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”),”
ABVC BIOPHARMA, INC. shareholders approved To approve an increase in the company’s Amended and Restated 2016 Equity Incentive Plan up to a maximum of 15% of current issued and outstanding shares at the 2024-04-16 meeting.
“For Against Abstain 4,483,481 96,204 6,415”
ABVC BIOPHARMA, INC. shareholders approved To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement dated February 23, 2023, and certain Securities Purchase Agr at the 2024-04-16 meeting.
“For Against Abstain 4,497,446 77,101 11,553”
ABVC BIOPHARMA, INC. shareholders approved To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-04-16 meeting.
“For Against Abstain 5,449,292 123,503 163,220”
ABVC BIOPHARMA, INC. shareholders approved To re-elect 11 directors to the Company’s board of directors at the 2024-04-16 meeting.
“Eugene Jiang 4,542,439 0 43,661”
ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) (effective 2024-04-16).
“On April 16, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (" Oncox "), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the “ Licensed Products ”), within North America for 20 years (the “ Oncox Agreement ”).”
ABVC BIOPHARMA, INC.: Amended Section 2.8 of Bylaws to reduce shareholder meeting quorum from a majority to 33-1/3% of votes entitled to be cast (effective 2024-03-14).
“the Board approved to amend Section 2.8 of the Company’s Bylaws to revise the number of shares needed to establish a quorum at shareholder meetings (the “Amendment”). The Amendment changes the quorum requirement from a majority to 33-1/3% of the votes entitled to be cast on a matter. The Amendment is effective as of March 14, 2024.”
ABVC BIOPHARMA, INC. reported financial results for the fiscal year ended December 31, 2023.
“ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.”
ABVC BIOPHARMA, INC. amended Amendment with Lind Global Fund II, LP valued at conversion price shall have a floor price of $1.00 (effective 2024-01-17).
“the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00 (the “Amendment”).”
ABVC BIOPHARMA, INC. amended Amendment to Note with Lind Global Fund II, LP valued at Conversion price floor of $1.00; cash payment to Lind if floor price triggered (effective 2023-11-20).
“We are filing this amendment to disclose that due to Nasdaq requirements, the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00 (the “Amendment”). Additionally, the Amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price.”
ABVC BIOPHARMA, INC. entered into Agreement with Shuling Jiang valued at approximately $2,962,232 (effective 2024-02-06).
“On February 06, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang shall transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).”
ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $1,000,000 (effective 2024-01-17).
“On January 17, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Lind Global Fund II, LP (“ Lind ”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,000,000 (the “ Offering ”), for a purchase price of $833,333”
ABVC BIOPHARMA, INC. amended amendment to the Note with Lind Global Fund II, LP.
“ntered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Lind Global Fund II, LP (“ Lind ”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,200,000 (the “ Offering ”),”
ABVC BIOPHARMA, INC. entered into a license with AiBtl BioPharma Inc. ("AIBL") valued at 23 million shares of AIBL stock ... $3,500,000 and royalties equaling 5% of net sales, up to $100 mi (effective 2023-11-12).
“In November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. ("BioLite") each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (" AIBL ") for the Company and BioLite’s CNS drugs”
ABVC BIOPHARMA, INC. reported third quarter ended September 30, 2023 results: revenue $15,884, net income The net loss was $3,368,080.
“achieved a total shareholders’ equity of $9.10M and therefore believes it has regained the compliance with NASDAQ’s shareholders’ equity requirement. ● Revenues . We generated $15,884 and $42,269 in revenues for the three months ended September 30, 2023 and 2022, respectively. The decrease in revenues was due to completion of ongoing projects and awaiting new”
ABVC BIOPHARMA, INC. amended Letter Agreement with Lind Global Fund II LP (effective 2023-09-12).
“On September 12, 2023, the Company and the Investor entered into a letter agreement (the “Letter Agreement”) pursuant to which the Investor agreed to waive any default, any Event of Default, and any Mandatory Default Amount (each as defined in the Note) associated with the Company’s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024.”
ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding stockholders equity.
“July 31, 2023, the Company issued 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction, the stockholders’ equity was increased by $1.75M. We also previously disclosed that on August 1, 2023, the holder of $500,000 of Notes (as hereinafter defined) converted such notes at $3.50 per share and received 142,857 shares of Common Stock. As a result of this conversion, the stockholders’ equity was increased by $0.5M. Additionally, as previ”
ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“August 8, 2023, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that for 10 consecutive business days, from July 25, 2023 to August 7, 2023, the closing bid price of the Company’s common stock has been at least $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Listing Rule 5550(a)(2) and has indicated that the matter is now closed. On August 10, 2023, the Company shall issue a press release announcing that the Company received the Notification L”
ABVC BIOPHARMA, INC. entered into Term Sheet with Xinnovation Therapeutics Co., Ltd. (effective 2023-07-31).
“On July 31, 2023, the Company entered into a binding term sheet (the “Term Sheet”) with Xinnovation Therapeutics Co., Ltd., a Company incorporated under the Law of People’s Republic of China (“Xinnovation”).”
ABVC BIOPHARMA, INC. entered into SPA with a certain institutional investor (effective 2023-07-27).
“the Company entered into certain securities purchase agreement, dated July 27, 2023 (the “ SPA ”), with a certain institutional investor (the “ Purchaser ”).”
ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at gross proceeds of $1,750,000 (effective 2023-07-27).
“ABVC BioPharma, Inc. (the “ Company ”) and certain investors (the “ Purchasers ”) entered into that certain securities purchase agreement on July 27, 2023 (the “ Purchase Agreement ”) relating to the offer and sale of 300,000 shares of common stock (the “ Shares ”), par value $0.001 per share (the “ Common Stock ”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share (the “ Pre-funded Warrants ”), in a registered direct offering (the “ Offering ”).”
ABVC BIOPHARMA, INC.: Filed a Certificate of Amendment to Articles of Incorporation to effect a 1-for-10 reverse stock split (effective 2023-07-25).
“ABVC BioPharma, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Certificate”) to be effective as of 12:01 a.m. EST on July 25, 2023 authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock”
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
“July 10, 2023,Nasdaq granted the Company an extension to comply with Listing Rule 5550(b)(1). The Company must now achieve compliance with this rule on or before August 31, 2023. If the Company fails to evidence compliance upon filing its periodic report for the quarter ending September 30, 2023, the Company may be subject to delisting. If Nasdaq determines to delist the Company’s securities, the Company will have an opportunity to appeal Nasdaq’s decision. At this time, the Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the symbol “ABVC”. SIGNATURE Pursuant t”
ABVC BIOPHARMA, INC. shareholders approved Reverse stock split authorization at the 2023-07-07 meeting.
“To approve granting the Board the authority to effect one or more reverse splits of the Company’s issued and outstanding Common Stock by a ratio of up to one-for-fifteen, at any time or from time to time, prior to July 7, 2024, with the exact timing and amount of each split to be determined by the Board in its sole discretion and file a Certificate of Amendment to the Company’s Articles of Incorporation regarding same.”
Dr. Uttam Yashwant Patil was appointed as Chief Executive Officer at ABVC BIOPHARMA, INC..
“The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.”
Dr. Howard Doong resigned as Chief Executive Officer at ABVC BIOPHARMA, INC..
“Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.”
Dr. Tsung-Shann (T.S.) Jiang was appointed as Chief Scientific Officer at ABVC BIOPHARMA, INC..
“The Company’s board of directors appointed Dr. Tsung-Shann (T.S.) Jiang to replace Dr. King as the Company’s CSO.”
Dr. Richard King resigned as Chief Scientific Officer at ABVC BIOPHARMA, INC..
“Dr. Richard King, the Company’s Chief Scientific Officer (“CSO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 13, 2023.”
ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000, and the Company’s stockholders’ equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company has 45 calendar days, or until July 10, 2023, to submit a plan to regain compliance. If the plan is accepted,”
ABVC BIOPHARMA, INC. shareholders approved Authorization of issuance of shares of common stock underlying convertible notes and warrants to Lind Global Fund II, LP in compliance with Nasdaq Listing Rule 5635(d) at the 2023-04-24 meeting.
“3. To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated February 23, 2023, by and among the Company and Lind Global Fund II, LP (“Lind”) , in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such convertible note and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants. For Against Abstain 18,835,192 115,688 529,236”
ABVC BIOPHARMA, INC. shareholders approved Ratification of the appointment of WWC P.C. CPA as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-04-24 meeting.
“2. To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023. For Against Abstain 19,388,899 86,207 5,010”
ABVC BIOPHARMA, INC. shareholders approved Re-election of 11 directors to the Company's board of directors, to serve until the 2024 annual meeting of shareholders at the 2023-04-24 meeting.
“1. To re-elect 11 directors to the Company’s board of directors (the “ Board ”), with such directors to serve until the 2024 annual meeting of shareholders. Name For Against Withheld Eugene Jiang 18,840,814 0 639,302 Norimi Sakamoto 18,796,356 0 683,760 Yen-Hsin Chou 18,833,715 0 646,401 Dr. Tsung-Shann (T.S.) Jiang 18,831,765 0 648,351 Hsin-Hui Miao 18,831,735 0 648,381 Yoshinobu Odaira 18,798,388 0 681,728 Dr. Tsang Ming Jiang 18,831,785 0 648,331 Dr. Chang-Jen Jiang 18,833,765 0 646,351 Che Wei Hsu 18,789,099 0 691,017 Shuling Jiang 18,855,080 0 625,036 Yu-Min (Francis) Chung 18,840,845 0 639,271”
ABVC BIOPHARMA, INC. reported the fiscal year ended December 31, 2022 results: revenue $969,783, net income $16,312,374.
“and operating results for the fiscal year ended December 31, 2022. Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. ● Revenues . We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in”
ABVC BIOPHARMA, INC. reported the fiscal year ended December 31, 2022 results: revenue $969,783, net income $16,312,374.
“ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results FREMONT, CA, March 31, 2023 -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022. Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. ● Revenues . We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in contract services with Rgene. ● Operating Expenses. Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021. Such increase in operating expenses was mainly attributable to the increase in stock-based compensation and selling, gene”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.